Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 2 of 11
Aug 20, 2026The argument is that investors and regulators are still willing to back pediatric rare cancer programs when biology, endpoints, and patient need are tightly aligned. The February renewal of the pediatric rare disease priority review voucher, after a lapse at the end of 2024, is presented as a key policy support for that thesis.
Michael Torres
Aug 18, 2026Quarterly biopharma venture capital deployment topped $10 billion last month for the third time since early 2022, and VC-backed exits reached a collective $34.4 billion. PitchBook argues that the lagged effect of that capital should begin showing up in pharma services demand in late 2026 or early 2027.
Emily Carter
Aug 17, 2026Two business signals emerged from STAT’s reporting on health care finance. UnitedHealth disclosed an IRS investigation that could raise its taxable income for 2017 through 2020 and potentially later years, while a separate report showed physician practice management deals are on track to run at about half last year’s level as state oversight expands.
Emily Carter
Aug 17, 2026Italy ranks tenth globally and fourth in Europe for overall research output, according to the Nature Index, but investors argue the more important shift is that financing and company-building infrastructure are becoming more dependable. The signal for healthcare investors is less about a sudden breakout than about whether Italy can keep more value onshore as startups scale.
Emily Carter
Aug 13, 2026Avalyn Pharma said it raised $345 million in an upsized IPO and began trading on Nasdaq April 30, while Generate Biomedicines raised $400 million earlier this year. The reporting shows that the public offering window may be more available in 2026, but only for teams that have already done the shareholder, governance, and execution work before the filing process starts.
Emily Carter
Aug 12, 2026As part of the 2027/2028 federal budget, the Austrian government has pledged backing for a dedicated capital growth fund that could translate into up to half a billion euros for Austrian companies. The fund is not biotech-only, but industry advocates are pushing for life sciences to capture a large share as Austria tries to convert research strength into larger domestic companies.
Emily Carter
Aug 10, 2026BlossomHill sold nearly 9.4 million shares at $16 and expects gross proceeds of $150 million, above an original $129.1 million target. Latigo’s offering rose to 19.2 million shares at $18 for expected proceeds of about $345.6 million, versus a previously targeted up to $285.2 million. The signal for investors is less about two debuts in isolation than about reopening appetite for clinical-stage biotech stories tied to clear capital deployment plans.
Daniel Cho
Aug 9, 2026The California cardiovascular biotech increased both the size and price of its offering, moving to 21.2 million shares at $18 apiece from an earlier range of $15 to $17 for 17.5 million shares. The proceeds are aimed at advancing BHB-1893 into Phase 3 development in hypertrophic cardiomyopathy, where Braveheart wants to compete with Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo.
Michael Torres
Aug 2, 2026Health technology companies drew significant attention in July 2026, with several large funding rounds announced that reflect both market optimism and the growing demand for transformative medical solutions. This roundup explores the most notable health tech deals, contextualizes their significance within broader industry trends, and examines what these investments could mean for patients, providers, and stakeholders.
Michael Torres
Jul 31, 2026Bullseye, the new event by MedCity News targeting healthcare investors and business development leaders, has quickly established itself as an essential forum for unconventional ideas on biopharma, risk, and the future of healthcare. The conference brought forth unapologetically direct viewpoints on industry bravery, the investor landscape, and the pressure to innovate.
Daniel Cho
Jul 29, 2026Reverse mergers are proving a viable route for venture-backed biotechs seeking public listings. Caldera Therapeutics and Vidya Therapeutics, both with assets in immunology and inflammation, have announced go-public deals that together raised $478 million. This trend highlights the evolving dynamics and investor strategies shaping the biotech capital markets in 2026.
Dr. Priya Nandakumar
Jul 26, 2026Candid Health's recent $120 million Series D financing signals a growing appetite among investors for AI-powered solutions aimed at streamlining healthcare administration. As the industry faces sustained financial pressures and regulatory complexity, automation of revenue cycle management is poised to play a transformative role.
Dr. Priya NandakumarMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.